These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26608081)

  • 21. Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).
    Rioux N; Smith S; Korpal M; O'Shea M; Prajapati S; Zheng GZ; Warmuth M; Smith PG
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):151-160. PubMed ID: 30386887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
    Zhou L; Dockens RC; Liu-Kreyche P; Grossman SJ; Iyer RA
    Drug Metab Dispos; 2012 Jun; 40(6):1093-103. PubMed ID: 22381334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
    Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
    Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
    Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
    Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2-p53 interaction, in rats, dogs and monkeys: in vitro-in vivo correlation.
    Ye Q; Jiang M; Huang WT; Ling Y; Olson SH; Sun D; Xu G; Yan X; Wong BK; Jin L
    Xenobiotica; 2015; 45(8):681-92. PubMed ID: 25798742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.
    Zhong CC; Chen F; Yang JL; Jia WW; Li L; Cheng C; Du FF; Zhang SP; Xie CY; Zhang NT; Olaleye OE; Wang FQ; Xu F; Lou LG; Chen DY; Niu W; Li C
    Acta Pharmacol Sin; 2018 Jun; 39(6):1048-1063. PubMed ID: 29620050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
    Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
    Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans.
    Clémence C; Fouqueray P; Sébastien B
    Drug Metab Dispos; 2020 Dec; 48(12):1330-1346. PubMed ID: 33020063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.
    Hosea NA; Collard WT; Cole S; Maurer TS; Fang RX; Jones H; Kakar SM; Nakai Y; Smith BJ; Webster R; Beaumont K
    J Clin Pharmacol; 2009 May; 49(5):513-33. PubMed ID: 19299532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2.
    Marathe P; Tang Y; Sleczka B; Rodrigues D; Gavai A; Wong T; Christopher L; Zhang H
    J Pharm Sci; 2010 Aug; 99(8):3579-93. PubMed ID: 20166197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
    Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo pharmacokinetics, disposition, and drug-drug interaction potential of tinengotinib (TT-00420), a promising investigational drug for treatment of cholangiocarcinoma and other solid tumors.
    Ni S; Li L; Sun X; Wang Y; Yu Q; Wang W; Gu Z; Yu Z; Wu D; Wu F; Jiang S; Peng P
    Eur J Pharm Sci; 2024 Jan; 192():106658. PubMed ID: 38048851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 - A potential oral treatment for tuberculosis.
    Kour G; Kumar A; Singh PP; Sharma S; Bhagat A; Vishwakarma RA; Ahmed Z
    Pulm Pharmacol Ther; 2016 Oct; 40():44-51. PubMed ID: 27457685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans.
    Eng H; Dantonio AL; Kadar EP; Obach RS; Di L; Lin J; Patel NC; Boras B; Walker GS; Novak JJ; Kimoto E; Singh RSP; Kalgutkar AS
    Drug Metab Dispos; 2022 May; 50(5):576-590. PubMed ID: 35153195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.
    Sharma R; Sun H; Piotrowski DW; Ryder TF; Doran SD; Dai H; Prakash C
    Drug Metab Dispos; 2012 Nov; 40(11):2143-61. PubMed ID: 22896728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor.
    Pasha MK; Jayaraman R; Reddy VP; Yeo P; Goh E; Williams A; Goh KC; Kantharaj E
    Drug Metab Lett; 2012 Mar; 6(1):33-42. PubMed ID: 22372550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans.
    Jayaraman R; Pasha MK; Williams A; Goh KC; Ethirajulu K
    Drug Metab Lett; 2015; 9(1):28-47. PubMed ID: 25600203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor.
    Mosure KW; Knipe JO; Browning M; Arora V; Shu YZ; Phillip T; Mcphee F; Scola P; Balakrishnan A; Soars MG; Santone K; Sinz M
    J Pharm Sci; 2015 Sep; 104(9):2813-23. PubMed ID: 25631585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti-glomerular basement membrane glomerulonephritis.
    Zheng W; Warner R; Ruggeri R; Su C; Cortes C; Skoura A; Ward J; Ahn K; Kalgutkar A; Sun D; Maurer TS; Bonin PD; Okerberg C; Bobrowski W; Kawabe T; Zhang Y; Coskran T; Bell S; Kapoor B; Johnson K; Buckbinder L
    J Pharmacol Exp Ther; 2015 May; 353(2):288-98. PubMed ID: 25698787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.